Repros Therapeutics Inc. (the “Company,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
Company profile
Website
CEO
Larry M. Dillaha
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Repros Therapeutics Inc, Zonagen Inc
SEC CIK
Corporate docs
IRS number
760233274
Latest filings (excl ownership)
15-12B
Securities registration termination
9 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
25-NSE
Exchange delisting
31 Jan 18
8-K
Completion of Acquisition or Disposition of Assets
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
Latest ownership filings
SC 13G/A
Repros Therapeutics Inc.
14 Feb 19
SC 13G/A
Repros Therapeutics Inc.
13 Feb 18
4
Katherine Anderson
31 Jan 18
4
Michael Wyllie
31 Jan 18
4
PATRICK FOURTEAU
31 Jan 18
4
Saira Ramasastry
31 Jan 18
4
DANIEL F CAIN
31 Jan 18
4
Nola E Masterson
31 Jan 18
SC 13G
Repros Therapeutics Inc.
2 Jan 18
SC 13G/A
Repros Therapeutics Inc.
2 Jan 18
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
News
Royalty Pharma Prices Offering Of $1.5B Of Senior Unsecured Notes
3 Jun 24
UBS Downgrades Royalty Pharma to Neutral, Announces $28 Price Target
3 Jun 24
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
28 May 24
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
23 May 24
Royalty Pharma Beats Q1 Earnings and Revenue Estimates
9 May 24
Press releases
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
4 Jun 24
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
3 Jun 24
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
28 May 24
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
22 May 24
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
22 May 24